Evogene (EVGN) Cash from Investing Activities (2013 - 2026)

Evogene has reported Cash from Investing Activities for 14 years, with the latest figure at -$4.5 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 83.48% year-over-year to -$4.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 million (down 79.69% YoY) and the FY2025 annual result came in at $17.7 million, up 84.35% from the prior year.
• Cash from Investing Activities retreated to -$4.5 million in Q1 2026 per EVGN's latest filing, from $10.3 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $12.0 million in Q1 2022 and troughed at -$4.5 million in Q1 2026.
• A 5-year average of $2.3 million and a median of $1.0 million in 2022 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities jumped 16663.64% in 2023, then sank 1534.87% in 2024.
• Over 5 years, Cash from Investing Activities stood at -$447000.0 in 2022, then slumped by 31.1% to -$586000.0 in 2023, then soared by 1594.54% to $8.8 million in 2024, then gained by 17.18% to $10.3 million in 2025, then tumbled by 143.71% to -$4.5 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$4.5 million, $10.3 million, and -$989000.0 for Q1 2026, Q4 2025, and Q2 2025 respectively.